kr1,957.00
1.11% yesterday
Copenhagen, Nov 20, 04:59 pm CET
ISIN
DK0010272202
Symbol
GMAB

Genmab A/S Stock price

kr1,957.00
-29.50 1.49% 1M
+618.00 46.15% 6M
+464.50 31.12% YTD
+512.00 35.43% 1Y
-1,215.00 38.30% 3Y
-335.00 14.62% 5Y
+1,116.50 132.84% 10Y
+1,833.00 1,478.23% 20Y
Copenhagen, Closing price Thu, Nov 20 2025
-22.00 1.11%
ISIN
DK0010272202
Symbol
GMAB
Industry

New AI Insights on Genmab A/S Insights AI Insights on Genmab A/S

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
kr121.8b
Enterprise Value
kr118.5b
Net debt
positive
Cash
kr3.4b
Shares outstanding
61.6m
Valuation (TTM | estimate)
P/E
82.0 | 112.9
P/S
34.0 | -
EV/Sales
33.1 | -
EV/FCF
98.5
P/B
21.2
Financial Health
Equity Ratio
80.1%
Return on Equity
22.3%
ROCE
21.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
kr3.6b | kr3.7b
EBITDA
kr1.4b | kr1.4b
EBIT
kr1.3b | kr1.2b
Net Income
kr1.5b | kr1.1b
Free Cash Flow
kr1.2b
Growth (TTM | estimate)
Revenue
24.7% | 19.6%
EBITDA
42.3% | 28.9%
EBIT
41.8% | 21.1%
Net Income
119.8% | -6.2%
Free Cash Flow
26.2%
Margin (TTM | estimate)
Gross
94.3%
EBITDA
38.7% | 37.0%
EBIT
36.9%
Net
41.4% | 28.6%
Free Cash Flow
33.6%
More
EPS
kr23.9
FCF per Share
kr19.5
Short interest
-
Employees
3k
Rev per Employee
kr1.2m
Show more

Is Genmab A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Genmab A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Genmab A/S forecast:

18x Buy
69%
6x Hold
23%
2x Sell
8%

Analyst Opinions

26 Analysts have issued a Genmab A/S forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Genmab A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,583 3,583
25% 25%
100%
- Direct Costs 205 205
82% 82%
6%
3,378 3,378
22% 22%
94%
- Selling and Administrative Expenses 597 597
16% 16%
17%
- Research and Development Expense 1,461 1,461
11% 11%
41%
1,387 1,387
42% 42%
39%
- Depreciation and Amortization 66 66
53% 53%
2%
EBIT (Operating Income) EBIT 1,320 1,320
42% 42%
37%
Net Profit 1,482 1,482
120% 120%
41%

In millions DKK.

Don't miss a Thing! We will send you all news about Genmab A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today